Search research articles
Contact Us
Filters
Showing results (1-10 of 38) with videos related to
Page
of 4
Sort By:
Journal of Clinical Pharmacology
|
June 14, 2005
Rheumatoid arthritis: an overview of new and emerging therapies
Tanya Doan, Elena Massarotti
Drugs of Today (Barcelona, Spain : 1998)
|
February 14, 2006
Rituximab
Tanya Doan, Elena Massarotti
Journal of Managed Care Pharmacy : JMCP
|
June 7, 2005
Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis
Daniel A Ollendorf, Elena Massarotti, Charles Birbara, et al.
JAMA
|
June 23, 2011
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis
Daniel H Solomon, Elena Massarotti, Rajesh Garg, et al.
Journal of Clinical Epidemiology
|
January 26, 2002
The Work Limitations Questionnaire's validity and reliability among patients with osteoarthritis
Debra Lerner, John I Reed, Elena Massarotti, et al.
ACR Open Rheumatology
|
May 16, 2020
Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients
Emma Stevens, Michael E Weinblatt, Elena Massarotti, et al.
Blood
|
January 10, 2015
Marked hyperferritinemia does not predict for HLH in the adult population
Alison M Schram, Federico Campigotto, Ann Mullally, et al.
Arthritis and Rheumatism
|
August 20, 2010
Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases
Laura R Rekedal, Elena Massarotti, Rajesh Garg, et al.
Arthritis Care & Research
|
January 29, 2014
Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial
Daniel H Solomon, Rajesh Garg, Bing Lu, et al.
RMD Open
|
April 26, 2016
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration
Michael Schiff, Michael E Weinblatt, Robert Valente, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 38) with videos related to
Sort By:
Page
of 4
Journal of Clinical Pharmacology
|
June 14, 2005
Rheumatoid arthritis: an overview of new and emerging therapies
Tanya Doan, Elena Massarotti
Drugs of Today (Barcelona, Spain : 1998)
|
February 14, 2006
Rituximab
Tanya Doan, Elena Massarotti
Journal of Managed Care Pharmacy : JMCP
|
June 7, 2005
Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis
Daniel A Ollendorf, Elena Massarotti, Charles Birbara, et al.
JAMA
|
June 23, 2011
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis
Daniel H Solomon, Elena Massarotti, Rajesh Garg, et al.
Journal of Clinical Epidemiology
|
January 26, 2002
The Work Limitations Questionnaire's validity and reliability among patients with osteoarthritis
Debra Lerner, John I Reed, Elena Massarotti, et al.
ACR Open Rheumatology
|
May 16, 2020
Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients
Emma Stevens, Michael E Weinblatt, Elena Massarotti, et al.
Blood
|
January 10, 2015
Marked hyperferritinemia does not predict for HLH in the adult population
Alison M Schram, Federico Campigotto, Ann Mullally, et al.
Arthritis and Rheumatism
|
August 20, 2010
Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases
Laura R Rekedal, Elena Massarotti, Rajesh Garg, et al.
Arthritis Care & Research
|
January 29, 2014
Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial
Daniel H Solomon, Rajesh Garg, Bing Lu, et al.
RMD Open
|
April 26, 2016
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration
Michael Schiff, Michael E Weinblatt, Robert Valente, et al.
Page
of 4